The consequences of Phase 3 trial failures are many. For patients, there can be a worsening of prognosis, quality of life, and/or emotional well-being. With the price of bringing a new drug to market hitting $2.6 billion these days, Phase 3 trials failures are costly for all stakeholders, including the patients involved clinical trials, the families who care for them, sponsors and investors, and employees engaged in clinical trial work.
In this complimentary webinar, a team of Clinipace experts will examine high-profile Phase 3 trial failures and discuss lessons learned. Tune into this no-cost, educational webinar to learn more about:
- Stats and facts about Phase 3 failures
- The most common causes of failure
- Lessons learned from recent case studies
- Insights for establishing successful clinical trials
Peter Langecker, MD, PhD, Executive Medical Director, Global Oncology, Clinipace Worldwide
Peter provides medical expertise within Clinipace, and externally, acting as Chief Medical Officer or Medical Monitor for sponsor medical projects. He provides clinical development strategy advice, feasibility assessments, and monitoring oversight for select clients. He has more than 25 years of experience in clinical oncology and oncology drug development, specializing in the planning and implementation of clinical Phase I-IV studies, regulatory strategy, and FDA and EMA interactions and submissions. Following his early career as Medical Monitor at Ciba-Geigy and Schering-Plough, he has served in senior roles in several pharmaceutical and biotechnology companies including Coutler, SUGEN, Intarcia, DURECT, and OXiGENE.
Peter received his MD and PhD in medical sciences from the Ludwig-Maximilians University.Message Presenter
Ron Marks, PhD, Chief Scientific Officer, Director of Biostatistics, Co-Founder, Clinipace Worldwide
Ron co-founded Clinipace Worldwide to bring to market an eClinical trial solution that he helped develop at the University of Florida. Ron and his team in the Division of Biostatistics developed a web-based electronic clinical trial system beginning in 1996 that was used to support a 22,000 patient Phase 4 cardiology clinical trial that ran at 870 primary physician sites in 10 countries for 5 years. Theuniversity received a patent on multiple aspects of the eClinical system.
Ron was trained as a Biostatistician. He received his MS and PhD in Statistics at the University of Florida and joined the Division of Biostatistics faculty at the J Hillis Miller Health Center at the University of Florida upon graduation. He served on the faculty for 30 years and as Director for 18 years.
Since joining Clinipace Worldwide, Ron has served as Chief Scientific Officer and Global Director of Biostatistics.Message Presenter
Barbara Geiger, BSN, RN, Executive Vice President, Oncology, Clinipace Worldwide
Barb has more than 25 years of experience in the conduct and management of Phase I-IV clinical trials and project teams. She has global expertise having run trials in more than 30 countries on six continents, and is still waiting for that trial in Antarctica!
Prior to founding Worldwide Clinical Research (WWCR) in 2000, she spent 10 years in leadership roles at global CROs. Additionally, Barb spent eight years at a major pharmaceutical company and began her career in clinical research in a Phase I/II Private research unit. She is a clinical operations professional and serves our clients as an executive liaison to project teams. An oncology nurse by training, she has extensive experience in oncology and CNS drug development.Message Presenter
Who Should Attend?
Senior level professionals from pharmaceutical and biotechnology companies involved in the planning or administration of Phase 2 and Phase 3 clinical trials.
- Clinical Affairs
- Clinical Operations
- Clinical Pharmacology
- Clinical Research & Development
- Clinical Trial Management
- Scientific & Medical Affairs
- Project Management
- Regulatory Affairs
- Trial Recruitment & Retention
- Clinical Monitoring
At Clinipace, a global, full-service contract research organization (CRO), our approach to clinical research is personal. We deliver a level of collaboration and flexibility not possible in a traditional CRO environment. Our personalized services and solutions, local regulatory expertise and therapeutic leadership are designed to face the most difficult industry challenges across all major therapeutic areas including oncology, gastroenterology, nephrology and urology. We strive to improve the way clinical research is performed and impact the future of health care using the most advanced technology and a CHALLENGE ACCEPTED approach.